MedTrace Logo

Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors

NCT00747253 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-08-24

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).

Conditions

Interventions

DEVICE

AutoLITT system

laser treatment with the AutoLITT system

Sponsors & Collaborators

  • Monteris Medical

    lead INDUSTRY

Principal Investigators

  • Gene Barnett, MD · The Cleveland Clinic

  • Andrew Sloan, MD · University Hospitals Cleveland Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-10-31
Completion
2010-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00747253 on ClinicalTrials.gov